Gordon Sanghera


Oxford Nanopore

About Gordon

Gordon Sanghera, CEO of Oxford Nanopore, the company that made the first ever portable DNA sequencer, used to sequence the genome of COVID-19 in China, which is now making machines for mass screening of coronavirus. Dr Sanghera’s PhD in bioelectronics sensing was followed by a career at MediSense an Oxford spin-out that delivered a new generation glucose technology to the market. Following the acquisition of MediSense by Abbott Laboratories Dr Sanghera held both UK and US VP and Director-level positions, including VP World Wide Marketing, Research Director and Manufacturing Process Development Director. Before its acquisition by Abbott, Gordon led the R&D of Medisense Inc. where he was instrumental in the launch of several generations of blood glucose bio-electronic systems for the consumer and hospital medical markets. He has also developed and validated production processes to meet with the regulatory requirements for USA and Europe.